Dexamethasone Posterior-Segment Drug Delivery System in the Treatment of Macular Edema Resulting from Uveitis or Irvine-Gass Syndrome

Williams, George A.; Haller, Julia A.; Kuppermann, Baruch D.; Blumenkranz, Mark S.; Weinberg, David V.; Chou, Connie; Whitcup, Scott M.

doi:10.1016/j.ajo.2008.12.033

Cited by 174 publications

(126 citation statements)

References 20 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroids can be used in several different ways such as topical, periocular or intravitreal. Intravitreal injection of triamcinolone and dexamethasone are reported to be effective in treatment of Irvine-Gass syndrome [20,21]. Sustained-release dexamethasone implant is a biodegradable ocular implant which is gradually release in around6-month period [21,22], treated 9 patients with Irvine-Gass syndrome with a dexamethasone implant and observed clinical improvement from baseline by 1 st month after treatment and it was remained throughout the 6-month.…”

Section: Discussionmentioning

confidence: 99%

“…Intravitreal injection of triamcinolone and dexamethasone are reported to be effective in treatment of Irvine-Gass syndrome [20,21]. Sustained-release dexamethasone implant is a biodegradable ocular implant which is gradually release in around6-month period [21,22], treated 9 patients with Irvine-Gass syndrome with a dexamethasone implant and observed clinical improvement from baseline by 1 st month after treatment and it was remained throughout the 6-month. But [23], did not observe any decrementinCMTuntil2 nd monthand recurrences were detected at the 3 rd month of treatment in which 49% their cases received a second injection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid

Altintas¹

2018

Int J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Irvine-Gass syndrome, is one of the most common causes of painless decrease in vision following even uneventful cataract surgery. It usually responds well to medical therapy, but, there are no widely acceptedconsensus on the effi cacy of various therapeutic options for the treatment of Irvine-Gass syndrome. The patient presenting in this case report, has systemic hypertension and chronic obstructive pulmonary disease and he use oral anti-hypertension medication and inhaler steroid. He diagnosed as Irvine-Gass syndrome due to presence of decrease in visual acuity and macular edema with hyporefl ective cystic intraretinal spaces in optical coherence tomography (OCT) since4th weekcontrol visitfollowing uneventful cataract surgery. After the responsiveness of several medications including topical steroid and non-steroidal anti-infl ammatory drugs and intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF), intravitreal sustainedrelease dexamethasone implant was applied. The visual acuity improved to 0.00 logMAR at 1st month after intravitreal dexamethasone therapy and consecutive OCT images showed complete resolution of macular edema with a normalization of the foveal profi le.The visual acuity and foveal architecture remained stable in 2-year follow-up period and additional treatment was not needed. To the best of our knowledge, this is the fi rst reportthatmentions the increment of visual acuity after a single dexamethasone implant, even though it did not response anti-VEGF combined with topical steroid and non-steroidal anti-infl ammatory drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid

Altintas¹

2018

Int J Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Refractory CME is defined in these studies as persistent CME with foveal thickness more than 250 μm and intraretinal cystic changes revealed by spectral domain optical coherence tomography, lasting for at least 90 days after the initiation of treatment. 23 Subset analysis in one of largest trials on this implant 26 found it to be effective in the treatment of Irvine-Gass syndrome with an acceptable safety profile. Two retrospective series 22,23 comprising 9 and 11 eyes, respectively, reported good results in patients who had several attempts at treatment.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine–Gass syndrome: a prospective case series

Sudhalkar

Chhablani

Vasavada

et al. 2016

Eye

View full text Add to dashboard Cite

“…Dexamethasone has a six-fold more potent anti-inflammatory pro file than triamcinolone acetonide (8) . A phase II study on the dexamethasone drug delivery system conducted a subgroup analysis that included patients with PCME and patients with uveitis (4,9) . A visual gain of at least 15 ETDRS letters was reported at the 90-day follow-up in 53.8% of the patients who were treated with 0.7 mg intravitreal dexamethasone implants (9) .…”

Section: Discussionmentioning

confidence: 99%

“…A phase II study on the dexamethasone drug delivery system conducted a subgroup analysis that included patients with PCME and patients with uveitis (4,9) . A visual gain of at least 15 ETDRS letters was reported at the 90-day follow-up in 53.8% of the patients who were treated with 0.7 mg intravitreal dexamethasone implants (9) . In the EPISODIC study, cases of ocular hypertension were reported but were controlled with pressure-lowering me dications.…”

Section: Discussionmentioning

confidence: 99%